Clinical trials: Malignant Mesothelioma
Malignant Pleural Mesothelioma
Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients
This is a multicenter retrospective analysis .The aim of the present study is to investigate the molecular predictors of vinorelbine response in tumor samples of a series of MPM patients and evaluate the possible impact on…
- Trial name
- NCT01865045
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Armando Santoro, MD
Mesotheliomas Pleural
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
This is a multicentric double-blind, placebo controlled, phase III trial. In this study, patients who underwent to a surgical resection of pleural mesothelioma and are without signs of macroscopic residual disease will be…
- Trial name
- AtezoMeso (NCT04996017)
- Testing
- Atezolizumab 1200 mg in 20 ML Injection
- Where
- 19 sites in Italy
- Volunteers
- 162 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Mesothelioma, Mesothelioma, Malignant
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit…
- Conditions
- Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural
- Trial name
- NCT03907852
- Testing
- gavo-cel, fludarabine, cyclophosphamide
- Where
- 11 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- TCR2 Therapeutics
Mesothelioma, Malignant
Niraparib Efficacy in Patient With Unresectable Mesothelioma
Multicentre, 2 arm, open-label UK randomised phase II trial to determine the efficacy of niraparib versus active symptom control (ASC) in patients who have relapsed after previously receiving platinum based systemic therapy.
- Trial name
- NERO (NCT05455424)
- Testing
- Niraparib Oral Product, Active Symptom Control
- Where
- 11 sites in United Kingdom
- Volunteers
- 88 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Malignant Pleural Mesothelioma, Non-small Cell Lung Cancer
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
A significant number of patients with malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC) are not cured with available treatments and will eventually relapse. After relapse treatment options are limited.
- Trial name
- NCT04480372
- Testing
- Gemcitabine, Atezolizumab
- Where
- 12 sites in Switzerland
- Volunteers
- 68 people
- Sponsor
- Swiss Cancer Institute
Peritoneal Carcinomatosis, Pseudomyxoma Peritonei
Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis
The investigator proposes to use the cardiac coherence technique to diminish anxiety before the surgery of a peritoneal carcinosis of colon or stomach or ovary and pseudomyxoma or peritoneal mesothelioma.
- Conditions
- Peritoneal Carcinomatosis, Pseudomyxoma Peritonei, Mesothelioma Peritoneum
- Trial name
- COCOON (NCT04024917)
- Testing
- Cardiac coherence, Standard care
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Mesothelioma
ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.
This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.
- Trial name
- NCT00040625
- Testing
- Pemetrexed, Cisplatin
- Where
- 6 sites in United States, Brazil and 2 more
- Sponsor
- Eli Lilly and Company
Malignant Peritoneal Mesothelioma
Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
The purpose of this study is to test the drug erlotinib (erlotinib hydrochloride) in people with malignant peritoneal mesothelioma who have a specific genetic mutation in their cancer.
- Trial name
- NCT01592383
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Chicago
Mesothelioma
SELECTmeso A Trial for Patients With Relapsed Malignant Mesothelioma SELECTmeso1 A Trial of BMS-986504 in Patients With MTAP-deficient Relapsed Mesothelioma
By incorporating a platform trial protocol design, SELECTmeso will spearhead a next-generation precision medicine trial platform in relapsed mesothelioma for the UK enabling early evaluation of hypothesis-driven targeted…
- Trial name
- SELECTmeso (NCT07602946)
- Testing
- BMS-986504
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Southampton
Malignant Mesothelioma
Capecitabine in Treating Patients With Malignant Mesothelioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have malignant…
- Trial name
- NCT00004183
- Testing
- capecitabine
- Where
- 50 sites in United States
- Volunteers
- 27 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Mesothelioma, Mesotheliomas Pleural
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit…
- Conditions
- Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum
- Trial name
- NCT05451849
- Testing
- TC-510, Fludarabine, Cyclophosphamide
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- TCR2 Therapeutics
Mesothelioma, Malignant, PD-L1 Negative
Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
Pembrolizumab plus autologous dendritic cell vaccine in patients with PD-L1 negative advanced mesothelioma who have failed prior therapies.This is an exploratory, single-arm, open-label, phase 1b clinical trial.
- Conditions
- Mesothelioma, Malignant, PD-L1 Negative, Advanced Cancer, Progressive Disease
- Trial name
- MESOVAX (NCT03546426)
- Testing
- Pembrolizumab, Autologous dendritic cells, Interleukin-2
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Pulmonary Edema, Pneumonia
Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
Dynamic digital radiography (DDR) is a new advanced version of chest radiography that captures dynamic images at a rate of 15 frames per second.
- Conditions
- Pulmonary Edema, Pneumonia, Atelectasis, Pleural Effusion
- Trial name
- NCT06538376
- Testing
- Portable Dynamic Digital Radiography (DDR)
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- Brigham and Women's Hospital
Malignant Mesothelioma
IP3R Modulation by Cancer Genes in Mesothelioma
Obtaining pleural biopsies in cases of malignant mesothelioma to detect molecular mechnisms and signal transduction
- Trial name
- NCT03558932
- Testing
- pleural biopsy
- Volunteers
- 20 people
- Sponsor
- KU Leuven
Liver Cancer, Anxiety Disorder
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
The study intervention consists of the early integration of palliative care services into standard oncology care in an outpatient setting for patients with advanced lung and non-colorectal gastrointestinal malignancies who are…
- Conditions
- Liver Cancer, Anxiety Disorder, Depression, Small Cell Lung Cancer
- Trial name
- NCT02349412
- Testing
- Early palliative care
- Where
- 23 sites in United States
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Pleural Mesothelioma
TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients
This is a phase I and II clinical study for patients with malignant pleural mesothelioma (a type of cancer affecting the lining of the lung).
- Trial name
- NCT02414945
- Testing
- Cyclophosphamide, Fludarabine, Autologous tumor infiltrating lymphocytes (TILs)
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- University Health Network, Toronto
Lung Cancer
Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma
The purpose of this study is to test the safety of the GL-ONC1 vaccinia virus at different dose levels. The investigators want to find out what effects, good and/or bad, it has on the patient and the malignant pleural effusion.
- Trial name
- NCT01766739
- Testing
- GL-ONC1
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Mesothelioma, Malignant Mesothelioma (MM)
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
Background: Mesothelioma is a rare cancer typically caused by exposure to asbestos and related fibers. Most people with mesothelioma survive less than 5 years after diagnosis.
- Conditions
- Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma
- Trial name
- NCT06654050
- Testing
- alrizomadlin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Tumor, Malignant Pleural Effusion
A Study of MT027 in Patients with Pleural Malignant Tumors
This is a phase I open label, single-arm, dose-escalation study to evaluate the feasibility, safety, tolerability, PK/PD, and to determine RP2D of MT027 via an locoregional delivery in subjects with pleural malignant tumors, who…
- Conditions
- Advanced Malignant Solid Tumor, Malignant Pleural Effusion, Pleura Carcinoma, Pleural Mesothelioma
- Trial name
- NCT06726564
- Testing
- MT027 cells suspension
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Suzhou Maximum Bio-tech Co., Ltd.
Non-Small Cell Lung Cancer and Pleural Mesothelioma
Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer
This is an open-label, two-arm, multicenter Phase IA/II dose-escalation study of PTK787 in combination with Pemetrexed alone (Cohort 1) or Pemetrexed and Cisplatin (Cohort 2).
- Trial name
- NCT00281125
- Testing
- PTK787 and Pemetrexed with or without Cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nevada Cancer Institute